Amylyx Pharmaceuticals, Inc. Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions
Amylyx Pharmaceuticals, Inc. (AMLX) had Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions of 8 Security as of 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Notes › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions · last filed 2024-05-09
- 2024-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions 8.00 Security.
- 2023-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions 1.00 Security.
- 2023-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions 8.00 Security.
- 2023-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions 14.00 Security.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions |
|---|---|
| 2024-03-31 | 8.00 Security 10-Q · filed 2024-05-09 |
| 2023-12-31 | 1.00 Security 10-K · filed 2024-02-22 |
| 2023-09-30 | 8.00 Security 10-Q · filed 2023-11-09 |
| 2023-06-30 | 14.00 Security 10-Q · filed 2023-08-10 |
| 2023-03-31 | 14.00 Security 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |